Cytosorbents Corporation

CTSO · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$20,719-$28,507-$32,813-$24,559
Dep. & Amort.$1,750$2,027$1,132$1,130
Deferred Tax$0$0$0$0
Stock-Based Comp.$3,760$3,701$3,800$6,204
Change in WC-$4,378$2,361-$3,562$642
Other Non-Cash$5,159-$1,236$3,208$2,577
Operating Cash Flow-$14,428-$21,655-$28,234-$14,006
Investing Activities
PP&E Inv.-$669-$936-$6,456-$4,281
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$669-$936-$6,456-$4,281
Financing Activities
Debt Repay.$10,000$0$5,000$0
Stock Issued$179$14,256-$40$715
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$848$218$0$0
Financing Cash Flow$9,331$14,474$4,960$715
Forex Effect-$85-$100-$263-$25
Net Chg. in Cash-$5,851-$8,217-$29,993-$17,596
Supplemental Information
Beg. Cash$15,615$23,832$53,825$71,422
End Cash$9,764$15,615$23,832$53,825
Free Cash Flow-$14,712-$22,591-$34,690-$18,287